Articles
Peptide articles & guides
Compound deep dives, dosing protocols, and the research behind them.
Editor's spotlight
Most popular this month
The single article our readers spent the most time with in May 2026.
ResearchPetrelintide: What Zealand and Roche's ZUPREME-1 Phase 2 Data Show
Petrelintide ZUPREME-1 Phase 2 evidence: Zealand and Roche's amylin monotherapy hit 10.7% weight loss at 42 weeks with placebo-like vomiting rates.
GuideGHK-Cu for Hair Loss: Topical and Injection Research Protocol
GHK-Cu for hair loss: copper tripeptide stimulates dermal papilla and follicle activity. Topical vs injectable protocols, evidence, and stack options.
ResearchGLP-1 Gallbladder Risk: Cholelithiasis, Cholecystitis, and What the Evidence Shows
GLP-1 gallbladder risk: what the He 2022 76-trial meta-analysis, STEP 1, Gong 2025 tirzepatide, and the 2025 FAERS pharmacovigilance signal actually show.
ResearchElecoglipron Phase 2: VISTA Obesity + SOLSTICE T2D Evidence
AstraZeneca's oral GLP-1 elecoglipron hit 11.8% weight loss in VISTA and 1.88% HbA1c drop in SOLSTICE. Here is what the Phase 2 trials actually show.
ResearchGLP-1s, Fertility & Long-Term Effects: What the Data Shows
GLP-1 receptors sit in the ovary. What the human data says about semaglutide, tirzepatide, fertility, the contraception interaction, and the long game.
ResearchPeptide Bioregulators and Longevity: The Khavinson Evidence
Peptide bioregulators and longevity: Khavinson's DNA-binding short peptides, epithalon telomerase, a 266-person mortality cohort, and the honest replication gap.
ResearchGLP-1s for Pediatric Obesity: STEP TEENS, SCALE Kids, SURPASS-PEDS
STEP TEENS, SCALE Teens, SCALE Kids, and SURPASS-PEDS now anchor pediatric GLP-1 evidence. Here is what the four Phase 3 obesity and T2D trials actually show.
ResearchBerobenatide: Pfizer's Monthly GLP-1, VESPER-3 Phase 2b Evidence
Pfizer's berobenatide hit ADA 2026 with VESPER-3 Phase 2b: 12.3% placebo-adjusted weight loss on monthly dosing. Here is what the trial actually shows.
ResearchBPC-157's Missing Human Data, Explained: Animal vs Clinical
BPC-157 has 40+ animal studies and essentially zero published human dose-finding trials. What the evidence proves, where 250 mcg came from, and the risks.
GuideThe Gray-Market Peptide Sourcing Truth: A 2026 Buyer's Guide
Where research peptides really come from, the $5-10B/yr US gray market, and exactly how to vet a source with COAs, HPLC, and mass spec before you ever buy.
ProtocolThe Trinity Physique Stack: GLP-1, GH and Androgens
The viral physique stack is three levers: a GLP-1 for fat loss, a GH secretagogue, and androgen modulation. The logic, the evidence, and the real risk.
ResearchGLP-1 Pancreatitis Risk: What the 2023 to 2026 Evidence Actually Shows
GLP-1 pancreatitis risk: what Sodhi 2023, the Nassar TriNetX cohorts, Wen 2025 meta-analysis, and 2025 cohort data show on semaglutide and tirzepatide.
NewsHuberman x Dr. Abud Bakri Peptides Episode: The Evidence
Our breakdown of the June 2026 Huberman Lab peptides episode with Dr. Abud Bakri: every major claim, plus what the human evidence actually shows you.
ResearchDihexa: BDNF Mimetic Dosing and the 7-Million-Times Hype Audit
Dihexa research: HGF-mimetic peptide marketed as 7 million times more potent than BDNF. Dosing protocols, the McCoy lab evidence, and the honest evaluation.
ResearchGLP-1s for Type 1 Diabetes: Tirzepatide Phase 2 and ADJUST-T1D Evidence
GLP-1s in type 1 diabetes: what the Snaith tirzepatide Phase 2, ADJUST-T1D semaglutide RCT, and ADJUNCT ONE liraglutide trial show on weight, A1c, and insulin.
ResearchCerebrolysin Protocol: Neurodegenerative Research and Stroke Recovery
Cerebrolysin neurodegenerative protocol guide: porcine brain-derived peptide mixture with EU/Asia approval. Stroke, Alzheimer's, dementia research evidence.
ResearchGLP-1s for PCOS: Semaglutide and Tirzepatide Evidence in 2026
GLP-1 for PCOS in 2026: what the Carmina, Jensterle, and 2025 metformin-combo trials, plus the 4,241-patient tirzepatide cohort, show on weight and fertility.
GuideSelank Nasal vs Injection: Dosing Guide and Onset Comparison
Selank nasal vs subcutaneous injection: dosing protocols, onset comparison, CNS bioavailability, and research applications for anxiolytic + cognitive endpoints.
ResearchGLP-1 Hair Loss: What the 2026 Cohort and Pharmacovigilance Data Show
GLP-1 hair loss with semaglutide and tirzepatide: 2026 TriNetX cohort (547,993 patients), FAERS RORs, telogen effluvium biology, and mitigation steps.
ComparisonTesofensine vs Phentermine vs Semaglutide: 2026 Weight Loss Compared
Tesofensine vs phentermine vs semaglutide comparison: mechanism, weight loss, side effects, and the practical decision framework for 2026 obesity research.
ResearchBimagrumab: What the BELIEVE Phase 2 Trial Actually Shows for GLP-1 Muscle Loss
BELIEVE Phase 2 (Nature Medicine 2026, PMID 41772149): bimagrumab + semaglutide hit 22.1% weight loss with 92.2% from fat mass. What the activin receptor data actually show.
ResearchGLP-1s and Cancer Risk: What 2024 to 2026 Meta-Analyses Actually Show
GLP-1 cancer risk: what 2024-2026 meta-analyses, the 1.6M-patient Wang cohort, and the 2026 Annals systematic review actually show across 13 cancer types.
GuideCompounded Tirzepatide 2026: Legal Access, Supply Status, and Pricing
Compounded tirzepatide 2026: shortage status, FDA enforcement, pricing vs branded Zepbound, quality and dose accuracy considerations for the year ahead.
ResearchMariTide GIP Antagonism: Why Blocking GIP Mimics Activating It
MariTide GIP antagonism mechanism: Amgen's monthly-dose GIP-antagonist + GLP-1 agonist produces ~20% weight loss. Why blocking GIP works like activating it.
ResearchVK2735 Phase 2 Evidence: Viking's Oral and Subcutaneous GLP-1/GIP Data
VK2735 Phase 2 evidence: Viking's dual GLP-1/GIP hit 14.7% weight loss subcutaneous and 12.2% oral at 13 weeks. Doses, safety, and what comes next.
ComparisonSermorelin vs CJC-1295 vs Ipamorelin: Which GH Secretagogue to Run
Sermorelin vs CJC-1295 vs Ipamorelin comparison: GHRH vs GHRP mechanism, half-life, pulse profile, cortisol risk, and which compound fits which research goal.
ResearchEloralintide: What Lilly's Phase 2 Amylin Data Actually Show
Eloralintide Phase 2 evidence: Lilly's selective amylin agonist hit 9.5 to 20.1% weight loss at 48 weeks. Mechanism, dose-response, and how it ranks.
GuideIGF-1 LR3: Research Dosing Protocol and Long-Half-Life Properties
IGF-1 LR3 research: Long R3 modification produces 20-30 hour half-life vs minutes for native IGF-1. Dosing, hypoglycemia risk, tumor concern, and protocol.
ResearchGLP-1s and Mental Health: What the 2024-2026 Evidence Actually Shows
FDA, EMA, and eight major real-world cohorts have now weighed in on GLP-1s and suicidal ideation. Here is what the 2024 to 2026 evidence shows.
GuideHexarelin: The Strongest GHRP, Dosing Guide and Cortisol Risk
Hexarelin research: synthetic hexapeptide GHRP with strongest GH release. Dosing, cortisol elevation risk, desensitization, and comparison vs Ipamorelin.
ResearchPemvidutide for MASH: IMPACT Phase 2b GLP-1/Glucagon Dual Agonist Evidence
Pemvidutide IMPACT Phase 2b for MASH: 58% resolution at 24 weeks (Lancet 2025), 7.5% weight loss at 48 weeks, and how the dual agonist actually compares.
ResearchFollistatin 344: Myostatin Pathway Research and the Gene Therapy Evidence
Follistatin 344 research: myostatin antagonist with strong gene-therapy efficacy data. Why injectable peptide form differs from the published clinical evidence.
ResearchSemaglutide and Thyroid Cancer: What the Human Data Show
Semaglutide carries a thyroid cancer boxed warning from rodent studies. What the largest human cohorts and 2025 to 2026 data actually show about the real risk.
ResearchACE-031 (Ramatercept): Myostatin Inhibitor Research Review
ACE-031 (ramatercept) myostatin inhibitor: DMD Phase 2 halted for safety in 2013. Mechanism, lean mass effects, and what the successor field looks like in 2026.
ResearchSemaglutide and Vision Loss: What the NAION Eye Data Show
Semaglutide and vision loss: what the NAION eye-risk studies show, how large the rare risk really is in absolute terms, and who should watch for it most.
ResearchGeneric Semaglutide Patent Expiry Timeline: 2026 to 2032 Roadmap
Generic semaglutide timeline: US patent expiry, biosimilar pathways, India/Canada launch windows, and what the price drop will look like through 2032.
NewsBryan Johnson at the Enhanced Games: Two Opposite Protocols
Bryan Johnson hosted the Enhanced Games as Human Enhancement Analyst. His Blueprint protocol runs opposite to the athletes he was analyzing. Here's why.
ResearchSemax: What the BDNF and Stroke Evidence Actually Shows
Semax peptide evidence reviewed: what the BDNF, cognitive, and stroke research actually shows, and why most of the human data is Russian and preclinical.
GuideTelehealth Peptide Prescriptions: State-by-State Legality 2026
Telehealth peptide prescription legality 2026: which states permit it broadly, which restrict to in-person evaluation, and how Ryan Haight Act rules apply.
ResearchGLP-1s Before Surgery: Aspiration Risk and How Long to Hold Them
What the research says about GLP-1s before surgery: aspiration risk, how long to hold semaglutide and tirzepatide, and where the 2024 guidance landed.
GuideCompounding Pharmacy Peptide Access in 2026: A Patient's Guide
Compounding pharmacy peptide access guide 2026: how to find a clinician, get a prescription, choose a 503A pharmacy, and what to expect for costs and timing.
ResearchSURPASS-CVOT: What Tirzepatide vs Dulaglutide Phase 3 Actually Showed
SURPASS-CVOT cut MACE 8% and all-cause death 16% with tirzepatide vs dulaglutide. Here is what the NEJM 2025 head-to-head Phase 3 trial actually shows.
ResearchGLP-1 Bone Density: What 2024-2026 Trials Show on Fracture Risk
GLP-1 bone density data in 2026: Hansen phase 2 RCT, Liu DXA cohort, and Kasher Meron fragility evidence on semaglutide and tirzepatide fracture risk.
NewsRetatrutide TRIUMPH-1: Phase 3 Hits 30.3% Weight Loss
Eli Lilly's retatrutide hit 30.3% weight loss in TRIUMPH-1 and 75.8% knee pain reduction in TRIUMPH-4. The triple-G just reset the obesity drug ceiling.
ReviewYucca Health Review 2026: Compounded GLP-1 Audit
Yucca Health holds 4.6 stars across nearly 1,000 Trustpilot reviews for compounded Tirzepatide+ and Semaglutide+. Our honest pricing and process audit.
ProtocolThymosin α-1 + BPC-157: Combined Immune and Recovery Protocol
Thymosin α-1 + BPC-157 stack: 1.6mg + 250mcg daily for combined T-cell immune modulation and tissue repair. Published mechanisms, dosing, when to run it.
ResearchSemaglutide for PAD: What the STRIDE Trial Actually Showed
STRIDE Phase 3b: semaglutide 1 mg for symptomatic PAD with type 2 diabetes gave 13% greater maximum walking distance at 52 weeks vs placebo plus ABI gains.
GuideLL-37 Cathelicidin: Human Antimicrobial Peptide Research Guide
LL-37 cathelicidin research: the only human cathelicidin antimicrobial peptide. Wound healing, biofilm, angiogenesis mechanism, plus dosing for research.
ComparisonTirzepatide vs Semaglutide: SURMOUNT-5 Head-to-Head at 72 Weeks
SURMOUNT-5 is the first peer-reviewed head-to-head of tirzepatide vs semaglutide for obesity: 20.2% vs 13.7% mean weight loss at 72 weeks. Full breakdown.
NewsJames Magnussen's Enhanced Games Stack: What He Actually Disclosed
James Magnussen disclosed his Enhanced Games pre-event protocol: testosterone, BPC-157, CJC-1295, Ipamorelin, Thymosin. Mechanism breakdown and evidence audit.
ResearchARA-290 (Cibinetide): EPO-Derived Peptide for Neuropathy Research
ARA-290 (cibinetide) research: erythropoietin-derived peptide for small fiber neuropathy and diabetic neuropathy. Innate Repair Receptor mechanism and dosing.
NewsFDA Peptide Reclassification Feb 2026: Complete Breakdown
FDA peptide reclassification: HHS Sec RFK Jr moved 14 of 19 peptides from Category 2 back to Category 1 on Feb 27, 2026. Full list and what it means for access.
ResearchAmycretin: GLP-1/Amylin Co-Agonist Phase 1 Evidence in 2026
Amycretin Phase 1 data: 24.3% mean weight loss subcutaneously at 36 weeks, 13.1% orally at 12 weeks. What Novo Nordisk's first-in-class molecule actually showed.
ResearchPentadeca Arginate (PDA): The BPC-157 Successor Evidence Audit
Pentadeca arginate (PDA) is the arginate-salt form of BPC-157 with 1000x oral stability. Mechanism, dosing, and the honest published evidence picture for 2026.
ResearchTirzepatide for MASH: What SYNERGY-NASH Phase 2 Actually Showed
Tirzepatide hit 62% MASH resolution at 15 mg in SYNERGY-NASH Phase 2. What the biopsy data, fibrosis numbers, and Phase 3 status mean for liver care.
GuideKPV Peptide: Oral α-MSH Tripeptide for Gut Inflammation Research
KPV peptide research: oral lysine-proline-valine tripeptide derived from α-MSH for IBD and gut inflammation. Dosing, PepT1 transporter, and IL-1β suppression.
ResearchSemaglutide SELECT Trial: 20% MACE Reduction in ASCVD Explained
SELECT trial: 17,604 adults with ASCVD and obesity, no diabetes. Semaglutide cut MACE 20%. Follow-on analyses show most CV benefit is not weight loss.
ReviewLimitless Biotech Review 2026: Honest Oral & Nasal Peptide Audit
An honest Limitless Biotech review: oral capsule and nasal spray catalog, the ENHANCED 15% off partner code, shipping mechanics, and Tier 2 COA standards.
ComparisonGLP-1 + Amylin Combinations 2026: CagriSema, Petrelintide, Amycretin
GLP-1 + amylin pipeline 2026: CagriSema 22.7%, petrelintide 10.7%, amycretin 14.5%. How the amylin pathway is reshaping obesity drug development this year.
ResearchGonadorelin for TRT in 2026: What the GnRH Evidence Actually Shows
Gonadorelin is GnRH. The pulsatile-pump trial evidence is real. The twice-daily TRT-adjunct protocol popular at telehealth clinics has zero RCTs behind it.
ComparisonOral Semaglutide vs Orforglipron: The 2026 Oral GLP-1 Comparison
Oral semaglutide (Rybelsus) vs orforglipron in 2026: dosing schedules, food rules, bioavailability differences, weight loss results, and how to choose.
ResearchSemaglutide for Knee Osteoarthritis: STEP 9 and the 2026 Cartilage Data
STEP 9 cut knee OA WOMAC pain by 41.7 points at 68 weeks with semaglutide 2.4 mg. New Cell Metabolism 2026 data shows a weight-loss-independent cartilage angle.
GuideWegovy HD 7.2 mg: STEP UP Trial, Dose Ladder, and Who It Is For
Wegovy HD (semaglutide 7.2mg) FDA approved March 2026 with 20.7% weight loss in STEP UP. Full titration schedule, side effect profile, and who should switch.
NewsEnhanced Games May 24: Opening-Day Stacks, Stakes, and What to Watch
Enhanced Games inaugural event May 21-24, 2026 at Resorts World Las Vegas. 40 athletes, $25M prize pool, disclosed peptide stacks, FDA reclassification context.
ComparisonGLP-1 Dosing Comparison 2026: From 2.4 mg to 7.2 mg and Beyond
GLP-1 dosing 2026: Wegovy HD 7.2mg now approved at 20.7%. Full dose-response comparison across semaglutide, tirzepatide, retatrutide, and orforglipron.
ResearchSemaglutide for CKD: What FLOW Phase 3 Actually Shows
FLOW Phase 3 cut major kidney events 24% with semaglutide in T2D and CKD. Here is what the trial showed, the safety profile, and how it fits the GLP-1 map.
GuideSLU-PP-332 Dosage Protocol: What the Preclinical Data Actually Shows
SLU-PP-332 dosage guide: published mouse studies used 50 mg/kg IP injection. Poor oral bioavailability. What this means for research-grade dosing in 2026.
ResearchGLP-1s for Alzheimer's: What EVOKE Phase 3 and ELAD Phase 2b Show
EVOKE Phase 3 found oral semaglutide did not slow early Alzheimer's at week 104. Here is what the GLP-1 Alzheimer's disease trial evidence actually shows.
GuideAOD-9604 Dosage Guide: Research Protocol and Phase IIb Reality Check
AOD-9604 dosage guide: 250-500 mcg daily SC. Phase IIb (536 subjects, 24wk) failed significance vs placebo. Honest 2026 reality check on this hGH fragment.
ResearchSetmelanotide (Imcivree): MC4R Agonist Evidence in 2026
Setmelanotide (Imcivree) MC4R agonist evidence in 2026: TRANSCEND, EMANATE, BBS Phase 3, POMC/LEPR data, dosing, side effects, and how it fits next to GLP-1s.
GuideTesofensine Dosage Guide: 0.25mg, 0.5mg, and 1mg Research Protocols
Tesofensine dosage guide: 0.5mg once daily produced 9.2% weight loss in 24wk Phase 2. Mechanism, side effects, half-life, and 2026 research positioning.
ResearchGLP-1s for Parkinson's: What LIXIPARK and Exenatide-PD3 Show
LIXIPARK showed lixisenatide slowed motor decline in Parkinson's. Exenatide-PD3 found nothing. Here is what the GLP-1 Parkinson's disease trials show.
ResearchMazdutide (IBI362): GLP-1/Glucagon Dual Agonist Phase 3 Evidence
Mazdutide (IBI362) GLP-1/glucagon dual agonist Phase 3 evidence: 14% weight loss in GLORY-1, HbA1c -2.15% in DREAMS-1, and how it stacks up to semaglutide.
GuideTB-500 Dosage Guide: Loading, Maintenance, and Reconstitution Math
TB-500 research dosing: 2.5mg twice weekly loading for 4-6 weeks, 2.5mg weekly maintenance, reconstitution math for 5mg vials, and stacking with BPC-157.
ResearchMaridebart cafraglutide (MariTide): once-monthly Phase 2 evidence
MariTide (maridebart cafraglutide) Phase 2 NEJM data: 16.2% weight loss at 52 weeks, GIPR antagonist plus GLP-1 agonist mechanism, and how it stacks up.
ReviewAscension Peptides Review 2026: Honest COA & Quality Audit
An honest Ascension Peptides review based on their public COA library, HPLC purity records, shipping mechanics, and the ENHANCED 50%-off partner code.
ResearchSemaglutide for MASH: ESSENCE Phase 3 vs Tirzepatide and Resmetirom
Semaglutide for MASH after the ESSENCE Phase 3 trial: 62.9% steatohepatitis resolution, fibrosis data, and how it compares to resmetirom and tirzepatide.
ProtocolSemaglutide 5mg Reconstitution: BAC Water Math & IU Chart
Semaglutide 5mg reconstitution chart with bacteriostatic water math and U-100 insulin syringe units per dose. Charts at 1, 2, 3, 5 mL volumes for clean dosing.
ProtocolHow Much Bacteriostatic Water for 10mg BPC-157? Full Chart
Exact bacteriostatic water math for a 10mg BPC-157 vial: concentration, syringe units per dose, and full reconstitution charts at 1, 2, 3, 5 mL volumes.
ResearchTirzepatide for HFpEF: What the SUMMIT Trial Actually Showed
SUMMIT cut cardiovascular death or worsening heart failure events 38% in obese HFpEF over 104 weeks. Here is what the tirzepatide trial shows in 2026.
ProtocolTirzepatide Reconstitution: 10mg & 15mg BAC Water Math and IU Chart
Tirzepatide reconstitution chart for 10mg and 15mg vials. BAC water math, U-100 insulin syringe IU per dose, and the SURMOUNT titration ramp.
GuideBPC-157 for Sale: COA-Verified Research-Use Vendor Guide
BPC-157 for sale with verified third-party COAs and ENHANCED discount. Vendor matrix, research-use legal status, shipping mechanics, and how to verify a lot.
ReviewWhere to Buy GHK-Cu in 2026: Format Guide and Vendor Comparison
Where to buy GHK-Cu in 2026: injectable vs oral vs topical format comparison, what to verify on COAs, and which research-grade vendor matches your endpoint.
ResearchSurvodutide: GCG/GLP-1 Dual Agonist Trial Evidence in 2026
Survodutide produced 16.6% weight loss in SYNCHRONIZE-1 and 62% MASH improvement in NEJM Phase 2. The full GCG/GLP-1 dual agonist trial evidence review.
GuideWhere to Buy Retatrutide in 2026: COA-Verified Vendor Guide
Where to buy Retatrutide in 2026 with verified third-party COAs and discount codes. Ascension R-30 vs R-10, FDA legal status, and how to verify before buying.
ProtocolRetatrutide 30mg Reconstitution Guide: BAC Water Math & IU Chart
Retatrutide 30mg reconstitution: BAC water math, insulin syringe units per dose, and charts for 1, 2, 3, 5 mL volumes. Plus storage tips for the vial.
GuideWhere to Buy BPC-157 in 2026: Verified COA & Vendor Guide
Where to buy BPC-157 with verified third-party COAs in 2026. Vendor matrix, FDA 503A compounding status, ENHANCED 50% code, and how to verify any lot.
ReviewBest Peptide Vendors 2026: COA-Verified Tier Ranking & Reviews
The best legit peptide vendors in 2026 ranked by COA transparency, HPLC purity, and shipping mechanics. Ascension, Limitless, STL, Direct Peptides, Swiss Chems.
Research5-Amino-1MQ: What the NNMT Inhibitor Research Actually Shows
5-Amino-1MQ is the most-studied NNMT inhibitor for fat loss and muscle stem cells. What the rodent evidence actually shows in 2026, and what is still missing.
NewsFDA July 2026 Peptide Compounding Review: Evidence by Compound
FDA's July 23-24 2026 PCAC meeting reviews BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon for 503A compounding. Here's the evidence by peptide.
ResearchOrforglipron Phase 3 Evidence: Lilly's Oral GLP-1 in 2026
Orforglipron hit 12.4% weight loss in ATTAIN-1 and beat oral semaglutide head-to-head in ACHIEVE-3. The full Phase 3 evidence for Lilly's oral GLP-1 in 2026.
ResearchSermorelin: What 30 Years of GHRH(1-29) Research Actually Show
Sermorelin (GHRH 1-29) was FDA-approved in 1997, withdrawn in 2008, and returned through compounding. Here is what three decades of clinical data show.
ResearchTirzepatide for Sleep Apnea: What SURMOUNT-OSA Actually Showed
SURMOUNT-OSA Phase 3 cut moderate-to-severe sleep apnea events by up to 62.8% vs placebo and earned the Zepbound FDA approval in late 2024. Here is the read.
ResearchStopping GLP-1s: What the Withdrawal Trials Actually Show
SURMOUNT-4 and STEP 1 put GLP-1 weight regain at 14% to 25% within a year of stopping. Here is the 2026 read on tirzepatide and semaglutide withdrawal.
ResearchKisspeptin in Humans: Libido, Fertility, and HPG Axis Research
Imperial College trials show kisspeptin boosts sexual brain processing and penile rigidity by 56%. Here is the full kisspeptin human evidence read for 2026.
ResearchSemaglutide for Alcohol Cravings: What the 2025 Research Shows
A 2025 JAMA Psychiatry RCT found semaglutide cut alcohol intake and weekly cravings in adults with AUD. Here is the full 2026 GLP-1 alcohol research read.
GuideNasal Peptides in 2026: Which Work, Which Don't
Nasal peptide bioavailability spans under 1% to near 30%. Here is what the 2026 clinical research shows about oxytocin, PT-141, Selank, Semax, and DSIP.
ResearchGLP-1 Muscle Loss: What the Research Shows in 2026
Semaglutide and tirzepatide trials put lean mass loss at 25-40% of total weight lost. Here is what the research says about preserving muscle on GLP-1 therapy.
GuideTesamorelin: The FDA-Approved GHRH Analog for Visceral Fat
Tesamorelin cut visceral fat 15.2% in 412 patients over 26 weeks. Here is what the GHRH analog does, how it compares to GLP-1s, and what safety shows.
GuideMOTS-c: The Mitochondrial Peptide That Mimics Exercise
MOTS-c doubled running capacity in old mice and improved insulin sensitivity by 30%. Here is what the research shows about this mitochondrial-derived exercise mimetic.
GuideMK-677: The Oral GH Secretagogue That Replaced My Injection Ritual
MK-677 (ibutamoren) is not a peptide. It is an oral ghrelin mimetic with a 24-hour half-life, real clinical data, and trade-offs you need to understand before starting.
GuidePT-141 (Bremelanotide): The Only FDA-Approved Peptide for Sexual Function
Bremelanotide works in the brain, not the blood vessels. Here is everything the research shows about the melanocortin peptide that treats desire itself, not just the plumbing.
ResearchSS-31 (Elamipretide): FDA-Approved Mitochondrial Peptide Guide
SS-31 (elamipretide) became the first mitochondrial peptide with FDA approval in 2025. Here are the clinical trial results for aging, vision, and muscle.
ResearchThymosin Alpha-1: The Most Tested Immune Peptide You Never Heard Of
Thymosin alpha-1 has 30+ clinical trials across 11,000 subjects and is approved in 35 countries. Here is what the data actually shows for immune function.
GuideCalm + Clarity: The Cognitive Stack for Focus Without the Fog
Three peptides, three distinct CNS pathways. How Selank, Pinealon, and PE 22-28 combine GABA modulation, neuroprotection, and TREK-1 channel activity into a single cognitive protocol.
GuideGLOW Blend: The Complete Recovery + Skin Protocol
GHK-Cu turns the Wolverine Stack into a three-compound skin and recovery powerhouse. Here's how collagen synthesis, angiogenesis, and cell migration work together, and the protocol to run it.
GuideKLOW Blend: 4-Peptide Skin, Gut, and Recovery Protocol
What happens when you add KPV's NF-kB inhibition to the GLOW stack. The gut-skin axis, IBD research, and the case for a four-compound protocol.
ResearchCagriSema: Cagrilintide + Semaglutide REDEFINE 1 Results
CagriSema delivered 20.4% weight loss at 68 weeks in REDEFINE 1. Here is what cagrilintide does and how the phase 3 data stacks up against tirzepatide.
GuideThe Wolverine Stack: BPC-157 + TB-500 Recovery Protocol
The two most-researched recovery peptides in a single vial. How BPC-157 and TB-500 complement each other mechanistically, practical dosing protocols, reconstitution math, and week-by-week expectations.
GuideThe FIT Stack: CJC-1295 + Ipamorelin GH Protocol
The gold standard GHRH + GHRP pairing for natural growth hormone optimization. Receptor-level synergy, practical dosing around sleep and fasting windows, reconstitution math, and realistic timelines.
GuideInjectable vs Oral Peptides: Bioavailability and What Matters
Oral capsules are convenient. Injectables are cheaper per dose. But bioavailability is only half the story. A compound-by-compound breakdown of which format serves which research goal.
NewsThe Enhanced Games: What the Peptide Community Needs to Know
A $1.2 billion sporting event where athletes openly use BPC-157, CJC-1295, and testosterone. Here is everything we know about the Enhanced Games heading into May 2026.
ComparisonRetatrutide vs Tirzepatide vs Semaglutide: 2026 GLP-1 Comparison
Three receptor agonists. Three weight loss profiles. A head-to-head on efficacy, side effects, half-life, and dose, with the 2026 trial data.
Protocol12-Week Retatrutide Titration Protocol: Research Dose Schedule
Mirrors the Phase 2 dose ladder to minimize GI side effects during escalation. Weekly targets, reconstitution math, and what trial data shows at each step.
ComparisonBPC-157 vs TB-500: Which Recovery Peptide Actually Works?
Both are touted for tissue repair, but the mechanisms and use cases are completely different. Here's when to use each, and when to stack them.
ComparisonTirzepatide vs Semaglutide: The 2026 Head-to-Head
The two most-studied GLP-1 compounds compared across weight reduction, glycemic control, and side effect profiles. Which one wins depends on your research question.
ProtocolCJC-1295 + Ipamorelin Stack: The Complete GH Research Protocol
Why pairing a GHRH with a GHRP produces more growth hormone than either alone, and the exact protocol the research community uses.
GuideNAD+ Injection Protocol: Dosing, Timing, and What the Research Shows
The coenzyme behind Huberman, Sinclair, and Attia's longevity protocols. How researchers dose injectable NAD+ and what to expect.
GuideBPC-157 Dosing Protocols: A Researcher's Complete Guide
How much, how often, where to inject, and what the literature actually supports. The definitive BPC-157 dosing reference for research.
ResearchRetatrutide Explained: Why It's the Most Effective Weight Peptide Yet
Retatrutide hit Phase 3: 28.7% weight loss at 12 mg over 68 weeks in TRIUMPH-4. Here is the verified mechanism, current trial readouts, and what is still missing.
GuidePeptide Reconstitution: The Complete Guide
BAC water, concentration math, syringe units, storage. Everything you need to know about reconstituting lyophilized peptides for research.
Stay in the loop
Subscribe by RSS
New research notes land regularly. Follow along in your reader of choice. No email required.
Open RSS feedSave 50% while you research
Code ENHANCED at Ascension
Everything we write about is sourced from Ascension Peptides: COA-verified, US-based, discreet shipping.
Shop with ENHANCED